PDLI Related Analyst Ratings
-
Piper Jaffray Starts PDL BioPharma (PDLI) at Neutral
-
Credit Suisse Downgrades PDL BioPharma (PDLI) to Underperform
-
Janney Montgomery Scott Starts PDL BioPharma (PDLI) at Neutral
-
Credit Suisse Starts PDL BioPharma (PDLI) at Neutral
-
ThinkEquity Starts PDL BioPharma (PDLI) at Hold
-
RBC Capital Downgrades PDL BioPharma (PDLI) to Sector Perform, Maintains Price Target
-
Global Hunter Securities Downgrades PDL BioPharma (PDLI) to Accumulate; Valuation Call
-
RBC Capital Initiates Coverage on PDL BioPharma (PDLI) with a Sector Perform
-
Global Hunter Securities Suggest Investors Acquire a Basket of Biotech Stocks
-
Global Hunter Securities Initiates Coverage on Several Biotech Stocks; Sees Glass "Half Full"
-
Lazard Downgrades PDL BioPharma (PDLI) to Hold
-
Lazard Upgrades PDL BioPharma (PDLI) to Buy
-
JP Morgan Upgrades PDL BioPharma (PDLI) to Neutral
-
J.P. Morgan Downgrades PDL BioPharma (PDLI) to Underweight
-
Credit Suisse Downgrades PDL BioPharma (PDLI) to Neutral
-
Wachovia downgrades PDL BioPharma (PDLI) to Market Perform
-
Broadpoint Capital Downgrades PDL BioPharma (PDLI) to Neutral
-
S&P Equity Research Downgrades PDL Biopharma (PDLI) to Hold
-
Lazard Capital Downgrades PDL Biopharma (PDLI) to Hold
-
Lehman Bros. Downgrades PDL BioPharma (PDLI) to Equalweight
-
Lehman Bros. Upgrades PDL BioPharma (PDLI) to Overweight
-
Who's The Next Biotech Target Following Celgene/Pharmion?
-
Credit Suisse Starts PDL BioPharma (PDLI) at Outperform
-
Wachovia upgrades PDL BioPharma (PDLI) to Outperform
-
Pacific Growth Downgrades PDL BioPharma (PDLI) to Neutral
-
CIBC downgrades PDL BioPharma (PDLI) to Sector Perform
-
JP Morgan downgrades PDL BioPharma (PDLI) to Neutral
-
First Albany upgrades PDL BioPharma (PDLI) to Buy
-
Cramer Makes Comments on PDLI and LAMR
-
Wachovia Downgrades PDL BioPharma (PDLI) to Market Perform
-
S&P Equity Research Downgrades PDL BioPharma Inc. (PDLI) to Hold
-
Rodman & Renshaw Comments on the "Aftershock" of MEDI/AZN Deal
-
Prudential upgrades PDL Biopharma (PDLI) to Overweight
-
First Albany upgrades PDL BioPharma (PDLI) to Neutral
-
Needham Highlights Biotech Companies Presenting at the Upcoming American Society of Hematology
-
First Albany downgrades PDL Biopharma (PDLI) to Underperform
-
Prudential downgrades PDL Biopharma (PDLI) to Neutral
-
Needham Starts PDL BioPharma (PDLI) at Buy
-
First Albany downgrades PDL Biopharma (PDLI) to Neutral
-
Deutsche Bank upgrades PDL BioPharma (PDLI) to Buy
-
William Blair Upgrades PDL BioPharma (PDLI) to Outperform
-
UPDATE: Citigroup upgrades PDL BioPharma (PDLI) to Buy on valuation
-
Citigroup upgrades PDL BioPharma (PDLI) to Buy on valuation
-
Deutsche Bank downgrades PDLI to Hold
-
Citigroup downgrades PDLI to Hold
-
Merrill Lynch List Top 2006 Biotech Picks
-
First Albany's Best Biotech Ideas for Q4
-
First Albany upgrades PDLI to Strong Buy
-
Wells Fargo Started PDLI at Buy
-
Banc of America Started PDLI at Buy
Back to PDLI Stock Lookup
